Identification of therapeutic targets, which are involved in the survival of CML LSCs such as bcl-2; the self-renewal such as sonic Hh, bmi-1, notch, and Wnt; and the block differentiation such as JAK2/STAT5 activation and HOX gene hypermethylation, will contribute to target LSCs effectively using combinations of small molecule inhibitors and demethylating agents. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.